Lung cancer
- Study type
- Review article
- Study name
- Lancet Seminar: Lung Cancer 2021
- Design
- Review article (Lancet Seminar)
- Sample size
- Not applicable (review article)
- Source
- The Lancet · 2021
In plain words
Lung cancer is one of the most common cancers and the leading cause of cancer death in the world. Over the past two decades, a better understanding of the biology of the disease and new treatments such as targeted therapies and immunotherapy have improved the outlook for many patients. This article reviews advances in screening, diagnosis and treatment.
Key results
Study population
This is a review article and no specific patients were enrolled. The review covers lung cancer, including non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).
Endpoints
This is a review article and no primary or secondary endpoints were defined.
Safety and side effects
This is a review article and no safety or adverse event data are reported in the abstract.
Clinical significance and place in guidelines
This review emphasises the importance of predictive biomarkers and the role of targeted therapies and immune checkpoint inhibitors in changing patient outcomes. The abstract names no specific clinical recommendation or drug; the status of treatment guidelines and approvals should be checked in up-to-date sources.
Limitations
This is a narrative review and presents no new primary data. The abstract does not describe the method of searching sources or selecting studies. The full text of the paper should be consulted for details.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.